+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID07407933

Evaluating Safety and Effectiveness of YL201 Combined with Atezolizumab for Advanced Solid Tumors Including Small Cell Lung Cancer

Led by MediLink Therapeutics (Suzhou) Co., Ltd. · Updated on 2026-09-17

118

Participants Needed

38

Research Sites

13 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, effectiveness, and how the body processes a drug called YL201 when combined with atezolizumab in patients with advanced solid tumors, including extensive-stage small cell lung cancer ES-SCLC. This phase IbII, open-label study involves two parts focusing on dose levels and optimization to understand the best way to use YL201 alongside atezolizumab. The study aims to find doses that patients can tolerate and that show potential benefits. Participants receive YL201 through an intravenous infusion on the first day of each 21-day cycle, at doses of 1.2 mgkg, 1.6 mgkg, or 2.0 mgkg, combined with a fixed 1200 mg dose of atezolizumab given the same way and schedule. The study starts with a dose escalation phase, then moves to dose optimization with random assignment to one of the three dosing groups. Depending on results, the study continues with dose expansion using one or two selected dose levels. Treatment continues until the cancer progresses, unacceptable side effects occur, or the participant chooses to stop. During the study, participants undergo evaluations of side effects and dose-limiting toxicities over 21 days, with ongoing monitoring of adverse events until disease progression or death, lasting up to about six years. Secondary outcomes include response rates, duration of response, progression-free and overall survival, and detailed drug pharmacokinetics for up to three years. The long participation allows researchers to gather extensive safety and effectiveness data while closely monitoring participants throughout their treatment journey.

CONDITIONS

Brief Title

A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors

Research Team

M

MediLink Study Team

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here